X-linked agammaglobulinemia medical therapy: Difference between revisions
Created page with "__NOTOC__ {{X-linked agammaglobulinemia}} {{CMG}} ==Overview== ==Medical Therapy== The most common treatment for XLA is an intravenous infusion of immunoglobulin ([[In..." |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
The most common treatment for XLA is an [[intravenous]] infusion of [[immunoglobulin]] ([[Intravenous immunoglobulin|IVIg]], human IgG antibodies) every 3-4 weeks, for life. IVIg is a human product extracted and pooled from thousands of [[blood]] donations. IVIg does not cure XLA but increases the patient's lifespan and quality of life, by generating [[passive immunity]], and boosting the [[immune system]]. | The most common treatment for XLA is an [[intravenous]] infusion of [[immunoglobulin]] ([[Intravenous immunoglobulin|IVIg]], human IgG antibodies) every 3-4 weeks, for life. IVIg is a human product extracted and pooled from thousands of [[blood]] donations. IVIg does not cure XLA but increases the patient's lifespan and quality of life, by generating [[passive immunity]], and boosting the [[immune system]]. With treatment, the number and severity of infections is reduced. With IVIg, XLA patients may a live relatively healthy life. A patient should attempt reaching a state where his [[IgG]] blood count exceeds 800 mg/Kg. The dose is based on the patient's weight and IgG blood-count. The dosing rule of thumb is 1g of IVIg for every 2kg of patient's weight. | ||
Muscle injections of immunoglobulin (IMIg) were common before IVIg was prevalent, but are less effective and much more painful, hence, IMIg is now uncommon. | Muscle injections of immunoglobulin (IMIg) were common before IVIg was prevalent, but are less effective and much more painful, hence, IMIg is now uncommon. | ||
| Line 13: | Line 13: | ||
One of the future prospects of XLA treatment is [[gene therapy]], which could potentially cure XLA. Gene therapy technology is still in its infancy and may cause severe complications such as cancer and even death. Moreover, the long term success and complications of this treatment are, as yet, unknown. | One of the future prospects of XLA treatment is [[gene therapy]], which could potentially cure XLA. Gene therapy technology is still in its infancy and may cause severe complications such as cancer and even death. Moreover, the long term success and complications of this treatment are, as yet, unknown. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 18:00, 21 September 2012
|
X-linked agammaglobulinemia Microchapters |
|
Differentiating X-linked agammaglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
X-linked agammaglobulinemia medical therapy On the Web |
|
American Roentgen Ray Society Images of X-linked agammaglobulinemia medical therapy |
|
Directions to Hospitals Treating X-linked agammaglobulinemia |
|
Risk calculators and risk factors for X-linked agammaglobulinemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
The most common treatment for XLA is an intravenous infusion of immunoglobulin (IVIg, human IgG antibodies) every 3-4 weeks, for life. IVIg is a human product extracted and pooled from thousands of blood donations. IVIg does not cure XLA but increases the patient's lifespan and quality of life, by generating passive immunity, and boosting the immune system. With treatment, the number and severity of infections is reduced. With IVIg, XLA patients may a live relatively healthy life. A patient should attempt reaching a state where his IgG blood count exceeds 800 mg/Kg. The dose is based on the patient's weight and IgG blood-count. The dosing rule of thumb is 1g of IVIg for every 2kg of patient's weight.
Muscle injections of immunoglobulin (IMIg) were common before IVIg was prevalent, but are less effective and much more painful, hence, IMIg is now uncommon.
Subcutaneous treatment (SCIg) was recently approved by the FDA, which is recommended in cases of severe adverse reactions to the IVIg treatment.
Antibiotics are another common supplementary treatment. Local antibiotic treatment (drops, lotions) are preferred over systemic treatment (pills) for long term treatment, if possible.
One of the future prospects of XLA treatment is gene therapy, which could potentially cure XLA. Gene therapy technology is still in its infancy and may cause severe complications such as cancer and even death. Moreover, the long term success and complications of this treatment are, as yet, unknown.